|
1
|
Cancer statistics, World Cancer Research
Fund International. http://www.wcrf.org/cancer_statistics/world_cancer_statistics.php.
http://www.wcrf.org/cancer_statistics/cancer_facts/women-breast-cancer.php.
Accessed: date?
|
|
2
|
Center for Cancer Control and Information
Services, National Cancer Center, Japan. Vital Statistics Japan.
Ministry of Health, Labour and Welfare; 2013
|
|
3
|
Hudis CA: Trastuzumab - mechanism of
action and use in clinical practice. N Engl J Med. 357:39–51. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neuoncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seidman AD, Fornier MN, Esteva FJ, Tan L,
Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, et
al: Weekly trastuzumab and paclitaxel therapy for metastatic breast
cancer with analysis of efficacy by HER2 immunophenotype and gene
amplification. J Clin Oncol. 19:2587–2595. 2001.PubMed/NCBI
|
|
8
|
Nahta R and Esteva FJ: Herceptin:
Mechanisms of action and resistance. Cancer Lett. 232:123–138.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nahta R, Yu D, Hung MC, Hortobagyi GN and
Esteva FJ: Mechanisms of disease: Understanding resistance to
HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol.
3:269–280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lewis GD, Figari I, Fendly B, Wong WL,
Carter P, Gorman C and Shepard HM: Differential responses of human
tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer
Immunol Immunother. 37:255–263. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Burris HA III, Tibbitts J, Holden SN,
Sliwkowski MX and Lewis Phillips GD: Trastuzumab emtansine (T-DM1):
A novel agent for targeting HER2+ breast cancer. Clin
Breast Cancer. 11:275–282. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
LoRusso PM, Weiss D, Guardino E, Girish S
and Sliwkowski MX: Trastuzumab emtansine: A unique antibody-drug
conjugate in development for human epidermal growth factor receptor
2-positive cancer. Clin Cancer Res. 17:6437–6447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barok M, Joensuu H and Isola J:
Trastuzumab emtansine: Mechanisms of action and drug resistance.
Breast Cancer Res. 16:2092014. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barok M, Tanner M, Köninki K and Isola J:
Trastuzumab-DM1 causes tumour growth inhibition by mitotic
catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Breast Cancer Res. 13:R462011. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barok M, Tanner M, Köninki K and Isola J:
Trastuzumab-DM1 is highly effective in preclinical models of
HER2-positive gastric cancer. Cancer Lett. 306:171–179. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Verma S, Miles D, Gianni L, Krop IE,
Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, et al
EMILIA Study Group: Trastuzumab emtansine for HER2-positive
advanced breast cancer. N Engl J Med. 367:1783–1791. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cox G, Vyberg M, Melgaard B, Askaa J,
Oster A and O’Byrne KJ: Herceptest: HER2 expression and gene
amplification in non-small cell lung cancer. Int J Cancer.
92:480–483. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: College of American Pathologists:
Recommendations for human epidermal growth factor receptor 2
testing in breast cancer: American Society of Clinical
Oncology/College of American Pathologists clinical practice
guideline update. Arch Pathol Lab Med. 138:241–256. 2014.
View Article : Google Scholar :
|
|
19
|
Dawood S, Broglio K, Buzdar AU, Hortobagyi
GN and Giordano SH: Prognosis of women with metastatic breast
cancer by HER2 status and trastuzumab treatment: An
institutional-based review. J Clin Oncol. 28:92–98. 2010.
View Article : Google Scholar :
|
|
20
|
Albain KS, Nag SM, Calderillo-Ruiz G,
Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS,
Reyes-Vidal JM, Sekhon JS, et al: Gemcitabine plus paclitaxel
versus paclitaxel monotherapy in patients with metastatic breast
cancer and prior anthracycline treatment. J Clin Oncol.
26:3950–3957. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aogi K, Yoshida M, Sagara Y, Kamigaki S,
Okazaki M, Funai J, Fujimoto T, Toi M, Saeki T and Takashima S: The
efficacy and safety of gemcitabine plus paclitaxel combination
first-line therapy for Japanese patients with metastatic breast
cancer including triple-negative phenotype. Cancer Chemother
Pharmacol. 67:1007–1015. 2011. View Article : Google Scholar
|
|
22
|
Takahara A, Koido S, Ito M, Nagasaki E,
Sagawa Y, Iwamoto T, Komita H, Ochi T, Fujiwara H, Yasukawa M, et
al: Gemcitabine enhances Wilms’ tumor gene WT1 expression and
sensitizes human pancreatic cancer cells with WT1-specific
T-cell-mediated antitumor immune response. Cancer Immunol
Immunother. 60:1289–1297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hernández-Vargas H, Rodríguez-Pinilla SM,
Julián-Tendero M, Sánchez-Rovira P, Cuevas C, Antón A, Ríos MJ,
Palacios J and Moreno-Bueno G: Gene expression profiling of breast
cancer cells in response to gemcitabine: NF-kappaB pathway
activation as a potential mechanism of resistance. Breast Cancer
Res Treat. 102:157–172. 2007. View Article : Google Scholar
|
|
24
|
Cao Y, Luo JL and Karin M: IkappaB kinase
alpha kinase activity is required for self-renewal of
ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl
Acad Sci USA. 104:15852–15857. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao N, Li S, Wang Z, Ahmed KM, Degnan ME,
Fan M, Dynlacht JR and Li JJ: NF-kappaB-mediated HER2
overexpression in radiation-adaptive resistance. Radiat Res.
171:9–21. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tzahar E, Waterman H, Chen X, Levkowitz G,
Karunagaran D, Lavi S, Ratzkin BJ and Yarden Y: A hierarchical
network of interreceptor interactions determines signal
transduction by Neu differentiation factor/neuregulin and epidermal
growth factor. Mol Cell Biol. 16:5276–5287. 1996.PubMed/NCBI
|
|
27
|
Spector NL and Blackwell KL: Understanding
the mechanisms behind trastuzumab therapy for human epidermal
growth factor receptor 2-positive breast cancer. J Clin Oncol.
27:5838–5847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
O’Brien NA, Browne BC, Chow L, Wang Y,
Ginther C, Arboleda J, Duffy MJ, Crown J, O’Donovan N and Slamon
DJ: Activated phosphoinositide 3-kinase/AKT signaling confers
resistance to trastuzumab but not lapatinib. Mol Cancer Ther.
9:1489–1502. 2010. View Article : Google Scholar
|
|
29
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoshida R, Tazawa H, Hashimoto Y, Yano S,
Onishi T, Sasaki T, Shirakawa Y, Kishimoto H, Uno F, Nishizaki M,
et al: Mechanism of resistance to trastuzumab and molecular
sensitization via ADCC activation by exogenous expression of
HER2-extracellular domain in human cancer cells. Cancer Immunol
Immunother. 61:1905–1916. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scaltriti M, Verma C, Guzman M, Jimenez J,
Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S,
Arribas J, et al: Lapatinib, a HER2 tyrosine kinase inhibitor,
induces stabilization and accumulation of HER2 and potentiates
trastuzumab-dependent cell cytotoxicity. Oncogene. 28:803–814.
2009. View Article : Google Scholar
|
